ERAS logo

ERAS Erasca, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$13.76
-0.13 (-0.94%)

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and …

Market Cap: $4.83Bwww.erasca.com

Price

$18.38+1167.59%
$1.39$8.42$15.44$22.47
Jul 2025Aug 2026

Social Signal Score

56
5d
54
7 mentions
+0.0%
30d
57
10 mentions
+0.0%
60d
56
15 mentions
+0.0%
90d
58
21 mentions
+0.0%
rss: 7 · news: 12 · marketaux: 2

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 2Sell 0Strong Sell 0
Avg price target$20.67+50.2%
Low $16Median $21High $24
Current Consensus

52-week range

$1.43$22.47
Last close
$18.38
Off 52w high
-18.2%
200-day average
$11.70
vs 200-day
+57.1%

Compare with other stocks off their highs

Revenue

$0.00
$0.00
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-0.44
$-0.45–$-0.43
8 analysts
FY2026
$-1.02
$-1.06–$-0.98
7 analysts
FY2027
$-0.75
$-0.90–$-0.61
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jonathan E. Lim
Sector
Healthcare
Industry
Biotechnology
Employees
103
Beta
0.65
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
32.43
www.erasca.com